News >

Selinexor Highly Active in Relapsed/Refractory AML

Published: Tuesday, Dec 19, 2017

Blood.jpgAlmost half of patients with relapsed/refractory acute myeloid leukemia (AML) achieved complete response (CR) with the combination of selinexor (KPT-330) and AraC-containing chemotherapy, according to data from a small prospective study presented at the 2017 ASH Annual Meeting.

Twenty patients experienced serious AEs, including 7 cases of sepsis and 4 cases of miscellaneous infection. Two patients died of lung infection/respiratory failure during the active treatment, 1 at 30 days and 1 at 60 days.
Uy GL, Rettig MP, Fletcher T, et al. Selinexor in combination with cladribine, cytarabine and G-CSF for relapsed or refractory AML. Presented at: American Society of Hematology 59th Annual meeting; December 9-12, 2017; Atlanta, GA. Abstract 816.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x